HUTCHMED Highlights SAVANNAH Trial Data Of Savolitinib Combo In Lung Cancer Setting

  • HUTCHMED (China) Limited HCM announced the first presentation of results from the ongoing SAVANNAH Phase 2 trial at the upcoming World Conference on Lung Cancer.
  • The study is evaluating savolitinib in combination with AstraZeneca Plc's AZN Tagrisso (osimertinib) in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer patients with mesenchymal epithelial transition receptor driven tumors, following disease progression on Tagrisso.
  • The abstract presents result from an analysis of 193 efficacy evaluable patients.
  • Across all patients in this analysis, the objective response rate (ORR) was 32%, the median duration of response (DoR) was 8.3 months, and the median progression-free survival (PFS) was 5.3 months. 
  • These results are consistent with the previously presented results from the TATTON global exploratory study in over 220 EGFR mutation-positive NSCLC patients.
  • Among the SAVANNAH patients who met the criteria for higher cut-off levels of MET aberration, ORR was 49%, median DoR was 9.3 months, and mPFS was 7.1 months.
  • In 2011, following its discovery and initial development by HUTCHMED, AstraZeneca and HUTCHMED entered a global licensing and collaboration agreement to develop and commercialize savolitinib jointly. 
  • Price Action: HCM shares are up 0.60% at $13.48 during the market session on the last check Wednesday.
Posted In: BiotechNewsGeneralBriefs